查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1565035

醣体学/糖生物学的全球市场

Glycomics / Glycobiology
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 249 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球醣体学/糖生物学市场将达到 64 亿美元

全球醣体学/糖生物学市场预计 2023 年为 21 亿美元，预计到 2030 年将达到 64 亿美元，2023-2030 年分析期间复合年增长率为 16.9%。酵素是本报告分析的细分市场之一，复合年增长率将达到 17.8%，预计到分析期结束时将达到 29 亿美元。分析期间，套件和试剂细分市场的复合年增长率预计为 16.8%。

美国市场预估价值5.929亿美元，中国预期复合年增长率16.0%

预计 2023 年美国醣体学/糖生物学市场规模将达 5.929 亿美元。中国作为世界第二大经济体，预计2030年市场规模将达到9.664亿美元，2023-2030年分析期间复合年增长率为16.0%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 14.9% 和 14.3%。在欧洲，德国的复合年增长率预计约为 12.2%。

全球醣体学/糖生物学市场 - 主要趋势和驱动因素总结

为什么醣体学/糖生物学成为生物技术和医学的一个主要领域？

醣体学，也称为糖生物学，正在成为生物技术和医学的一个重要领域，因为它在理解复杂的生物过程和推进治疗方法发挥关键作用。但为什么醣体学在今天如此重要呢？糖生物学是一个全面研究糖链的研究领域，糖链是与蛋白质和脂质结合的复杂碳水化合物，参与细胞讯号传导、免疫反应和疾病进展等多种生物功能。糖生物学专注于这些糖分子如何影响细胞通讯、疾病机制以及新诊断和治疗方法的开发。

糖生物学的研究对人类健康有广泛的影响，因为聚醣在癌症、自体免疫疾病和感染疾病等疾病的进展中发挥着重要作用。透过破解聚醣的结构和功能，研究人员正在发现早期诊断疾病、开发更有针对性的治疗方法以及开发更有效的疫苗的新方法。此外，醣质学对于理解药物交互作用和设计生技药品至关重要，而生物製剂正成为精准医学的重要工具。随着个人化医疗保健变得越来越重要，醣质学正在帮助揭示身体在分子层面上如何运作的新见解，推动诊断、治疗和疫苗开发的创新。

科技进步如何加速醣质学的研究与应用？

技术进步在推进醣质学研究方面发挥着至关重要的作用，使破解聚醣的复杂性并揭示其在生物系统中的多样化功能成为可能。一项重要的进展是高通量聚醣分析技术的发展，例如层析法(LC)，这使得聚醣结构的快速识别和表征成为可能。这些工具使研究人员能够比以往更快、更精确地绘製生物体或组织中的聚醣或醣组图。这种能力对于理解聚醣在组织、个体和疾病状态之间的差异至关重要，为更个人化的治疗铺平了道路。

另一项重要的技术进步是将生物资讯工具应用于醣质学研究。聚醣结构复杂，具有众多的分支和多样化的组成，需要复杂的计算方法来分析和解释。机器学习和人工智慧 (AI) 的进步使得开发能够预测聚醣结构与蛋白质和脂质之间相互作用的演算法成为可能。这些生物资讯工具将帮助研究人员识别疾病的聚醣生物标记物，开发基于聚醣的疗法，并揭示聚醣变化如何参与疾病进展。人工智慧主导的分析使科学家能够筛选大量的聚醣资料，以更有效地识别模式和潜在的治疗标靶。

合成糖生物学的进步也透过实现合成聚醣的设计和生产而改变了这个领域。这些合成聚醣模仿天然存在的分子，用于疫苗开发、药物发现和治疗研究。例如，研究人员可以创建特定的聚醣结构来研究病原体如何与人类细胞相互作用或开发引发强烈免疫反应的疫苗。这种能力对于开发针对流感和冠状病毒等复杂病毒的疫苗尤其重要，其中聚醣在免疫逃脱中发挥关键作用。此外，合成聚醣可用于开发针对癌细胞上特定受体或调节免疫反应的基于聚醣的药物，为精准医学开闢新途径。

另一个进展领域是使用先进的成像技术，例如冷冻电子显微镜（cryo-EM）和聚醣阵列技术。这些工具使我们能够在分子层面上可视化聚醣如何与其他生物分子相互作用。这对于理解聚醣在细胞信号传导、病原体识别和免疫系统功能等过程中的作用至关重要。例如，聚醣阵列能够高通量筛检碳水化合物与蛋白质的相互作用，从而揭示癌症和神经退化性疾病等疾病的潜在药物标靶和生物标记。这些影像和筛检技术可以更深入地了解聚醣在健康和疾病中的动态作用。

为什么醣质学对于阐明疾病机制、开发诊断方法和推进治疗方法至关重要？

由于聚醣在控制生物过程和疾病进展中发挥重要作用，因此醣质学对于了解疾病机制、开发诊断方法和推进治疗方法至关重要。聚醣几乎参与细胞功能的各个方面，从蛋白质折迭和稳定性到免疫系统活化和细胞间通讯。聚醣结构的变化通常与疾病状态有关，这使得醣体学成为在分子层面上识别生物标记和了解疾病机制的宝贵工具。

醣质学对医学最重要的贡献之一是能够发现用于早期检测疾病的生物标记。糖基化（糖链附着在蛋白质和脂质上的过程）的变化经常在癌症、糖尿病和感染疾病等疾病中观察到。例如，异常的聚醣模式是癌细胞的标誌，可以促进肿瘤生长、转移和免疫逃脱。透过识别这些改变的聚醣特征，研究人员可以开发出更灵敏、更特异性的诊断测试。基于聚醣的生物标记有可能彻底改变早期疾病检测，使临床医生能够识别癌症、肝病和神经退化性疾病等具有高治疗潜力的疾病，从而实现早期诊断。

在治疗方面，醣体学正在帮助开发更有针对性和更有效的治疗方法。聚醣结构可以作为药物的靶点，特别是在涉及异常糖基化的疾病中。例如，某些类型的癌症在其表面蛋白上表现出特异性的聚醣模式，而醣质学研究已经开发出特异性针对这些异常聚醣的治疗方法。这些针对聚醣的治疗提供了一种更精确的治疗方法，专注于患病细胞，同时最大限度地减少对健康组织的损害。醣组学也有助于设计基于聚醣的疫苗，增强对病原体和癌细胞的免疫识别。聚醣在免疫系统识别外敌方面发挥重要作用，含有合成聚醣的疫苗可以引发更强、更特异性的免疫反应。

糖工程对于生技药品的开发也至关重要，生物製剂是一类不断增长的治疗方法，包括单株抗体、基因疗法和基于细胞的疗法。许多生技药品（例如治疗性抗体）的稳定性、有效性和安全性都依赖糖基化。了解和控制药物製造过程中的糖基化模式对于确保生技药品正确发挥作用并对患者安全至关重要。 Glycomics 提供了在生产过程中监测和优化糖基化所需的工具，帮助製药公司开发更有效且一致的生物製药。

除了治疗和诊断药物之外，糖组学在个人化医疗的进步中也发挥着至关重要的作用。由于遗传和环境因素的不同，聚醣模式可能有所不同，因此了解这些变化可以帮助开发针对患者独特的聚醣谱的个人化治疗。这对于癌症尤其重要，因为肿瘤通常表现出特异性的聚醣模式，并且可以针对个人化治疗进行针对性治疗。随着醣体学领域的不断发展，它将在塑造精准医学的未来方面发挥越来越重要的作用，从而实现根据个别患者的分子特征定制更有效的治疗方法。

推动醣质学/糖生物学市场成长的因素有哪些？

醣体学/糖生物学市场的快速成长是由几个关键因素推动的，包括个人化医疗需求的不断增长、药物开发的进步、复杂疾病盛行率的增加以及聚醣分析的技术创新等因素。首先，个人化医疗的推广是醣质学市场的驱动因素。随着医疗保健从一刀切的方法转向更个人化的治疗，醣体学提供了工具来识别可用于个人化治疗的独特聚醣谱。这在肿瘤学中尤其重要，因为癌细胞经常表现出特异性的聚醣改变，并且可以针对这些变化进行更有效的治疗。用于早期疾病检测和个人化治疗策略的聚醣生物标记的可用性正在增加研究和临床环境中对醣体学技术的需求。

其次，药物开发的进步，特别是生技药品和单株抗体领域的进步，正在促进醣体学市场的成长。许多生物製药的活性、稳定性和安全性都依赖糖基化，在药物製造过程中控制这些糖基化结构对于创造有效的治疗方法至关重要。製药公司正在增加对醣质学工具和技术的投资，以优化生物製药的糖基化，并确保这些治疗符合最高的功效和安全标准。这种对药物开发精度的需求正在推动醣质学在製药业的应用。

第三，癌症、自体免疫疾病和神经退化性疾病等复杂疾病的日益普及正在推动对先进诊断和治疗解决方案的需求。醣体学具有独特的优势，可以深入了解付加的变化如何参与疾病进展，从而满足这一需求。例如，基于聚醣的生物标记正在开发用于癌症的早期检测，并且正在研究针对聚醣的治疗方法作为自体免疫疾病和感染疾病的新治疗方法。随着这些疾病的全球负担持续增加，对基于醣体学的解决方案的需求预计将显着增长。

聚醣分析的技术创新也支持醣体学市场的扩张。质谱、聚醣阵列和生物资讯学工具的进步使研究人员能够更快、更准确、更高解析度地分析聚醣。这些技术使科学家能够更轻鬆地绘製糖组图、识别疾病特异性聚醣变化以及开发新的基于聚醣的治疗方法。高通量聚醣分析工具的日益普及正在加速研究并扩大醣体学在诊断、治疗和疫苗开发等领域的商业性潜力。

此外，增加醣体学研究资金和建立专门的醣体学研究中心也有助于市场成长。政府、学术机构和私人公司正在大力投资醣质学学研究，因为它具有改变医疗保健的潜力。学术界、工业界和医疗保健提供者之间的合作正在推动醣质学在临床中的应用，进一步推动对醣质学工具和技术的需求。

总之，醣体学/糖生物学市场的成长是由个人化医疗需求的增加、药物开发的进步、复杂疾病盛行率的增加以及聚醣分析的技术创新所推动的。随着醣体学继续深入了解聚醣在健康和疾病中的作用，它将在塑造广泛的医疗和工业应用中的诊断、治疗和精准医学的未来方面发挥重要作用。

受访企业范例（共152家）

  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Merck KgaA
  • New England Biolabs, Inc.
  • Prozyme, Inc.
  • Shimadzu Corporation
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Waters Corporation

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他领域

第四章 比赛

简介目录
Product Code: MCP12203

Global Glycomics / Glycobiology Market to Reach US$6.4 Billion by 2030

The global market for Glycomics / Glycobiology estimated at US$2.1 Billion in the year 2023, is expected to reach US$6.4 Billion by 2030, growing at a CAGR of 16.9% over the analysis period 2023-2030. Enzymes, one of the segments analyzed in the report, is expected to record a 17.8% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Kits & Reagents segment is estimated at 16.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$592.9 Million While China is Forecast to Grow at 16.0% CAGR

The Glycomics / Glycobiology market in the U.S. is estimated at US$592.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$966.4 Million by the year 2030 trailing a CAGR of 16.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.9% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Glycomics / Glycobiology Market - Key Trends and Drivers Summarized

Why Is Glycomics/Glycobiology Emerging as a Key Field in Biotechnology and Medicine?

Glycomics, also referred to as glycobiology, is becoming an essential field in biotechnology and medicine due to its critical role in understanding complex biological processes and advancing therapeutic solutions. But why is glycomics so vital today? Glycomics is the comprehensive study of glycans—complex carbohydrates that attach to proteins and lipids and are involved in a wide variety of biological functions, including cell signaling, immune response, and disease progression. Glycobiology focuses on how these sugar molecules influence cellular communication, disease mechanisms, and the development of new diagnostics and treatments.

The study of glycomics has far-reaching implications for human health, as glycans play a crucial role in the progression of diseases such as cancer, autoimmune disorders, and infections. By decoding the structure and function of glycans, researchers are uncovering new ways to diagnose diseases earlier, develop more targeted therapies, and create more effective vaccines. Moreover, glycomics is critical for understanding drug interactions and designing biologics, which are rapidly becoming essential tools in precision medicine. As the importance of personalized healthcare grows, glycomics is helping to unlock new insights into how the body functions at a molecular level, driving innovation in diagnostics, therapeutics, and vaccine development.

How Are Technological Advancements Accelerating Research and Applications in Glycomics?

Technological advancements are playing a pivotal role in advancing glycomics research, making it possible to decode the complexities of glycans and uncover their diverse functions in biological systems. One significant advancement is the development of high-throughput glycan analysis techniques, such as mass spectrometry (MS) and liquid chromatography (LC), which allow for the rapid identification and characterization of glycan structures. These tools enable researchers to map the glycome—the entire set of glycans in an organism or tissue—faster and with greater accuracy than ever before. This capability is crucial for understanding how glycans differ across tissues, individuals, or disease states, paving the way for more personalized medical treatments.

Another key technological advancement is the application of bioinformatics tools to glycomics research. The complexity of glycan structures, with their numerous branches and diverse configurations, requires sophisticated computational methods for analysis and interpretation. Advances in machine learning and artificial intelligence (AI) are enabling the development of algorithms that can predict glycan structures and their interactions with proteins and lipids. These bioinformatics tools help researchers identify glycan biomarkers for diseases, develop glycan-based therapeutics, and uncover how glycan alterations contribute to disease progression. With AI-driven analytics, scientists can sift through vast amounts of glycomic data to identify patterns and potential therapeutic targets more efficiently.

Advances in synthetic glycobiology are also transforming the field by enabling the design and production of synthetic glycans. These synthetic glycans mimic naturally occurring molecules and are used in vaccine development, drug discovery, and therapeutic research. For instance, researchers can create specific glycan structures to study how pathogens interact with human cells or to develop vaccines that elicit strong immune responses. This capability is particularly important for developing vaccines for complex viruses like influenza and coronaviruses, where glycans play a key role in immune evasion. Additionally, synthetic glycans are being used in the development of glycan-based drugs that target specific receptors on cancer cells or modulate immune responses, opening new avenues for precision medicine.

Another area of advancement is the use of advanced imaging techniques, such as cryo-electron microscopy (cryo-EM) and glycan array technology. These tools allow scientists to visualize how glycans interact with other biomolecules at the molecular level. This is crucial for understanding the role of glycans in processes like cell signaling, pathogen recognition, and immune system function. Glycan arrays, for example, enable the high-throughput screening of glycan interactions with proteins, which can reveal potential drug targets or biomarkers for diseases like cancer and neurodegenerative disorders. These imaging and screening technologies are providing deeper insights into the dynamic role of glycans in health and disease.

Why Is Glycomics Critical for Understanding Disease Mechanisms, Developing Diagnostics, and Advancing Therapeutics?

Glycomics is critical for understanding disease mechanisms, developing diagnostics, and advancing therapeutics because glycans play a fundamental role in regulating biological processes and disease progression. Glycans are involved in nearly every aspect of cellular function, from protein folding and stability to immune system activation and cell-cell communication. Alterations in glycan structures are often associated with disease states, making glycomics an invaluable tool for identifying biomarkers and understanding disease mechanisms at a molecular level.

One of the most important contributions of glycomics to medicine is its ability to uncover biomarkers for early disease detection. Changes in glycosylation—the process by which glycans attach to proteins or lipids—are frequently observed in diseases like cancer, diabetes, and infectious diseases. For example, abnormal glycan patterns are a hallmark of cancer cells, where they can promote tumor growth, metastasis, and immune evasion. By identifying these altered glycan signatures, researchers can develop more sensitive and specific diagnostic tests. Glycan-based biomarkers hold the potential to revolutionize early disease detection, allowing clinicians to diagnose conditions like cancer, liver disease, and neurodegenerative disorders at earlier stages, when treatments are more likely to be effective.

In therapeutics, glycomics is enabling the development of more targeted and effective treatments. Glycan structures can serve as drug targets, particularly in diseases where abnormal glycosylation is involved. For instance, certain cancers exhibit unique glycan patterns on their surface proteins, and glycomics research is leading to the development of therapies that specifically target these aberrant glycans. These glycan-targeting therapies offer a more precise approach to treatment, minimizing damage to healthy tissues while focusing on the diseased cells. Glycomics is also contributing to the design of glycan-based vaccines that enhance immune recognition of pathogens or cancer cells. Glycans play a crucial role in how the immune system identifies foreign invaders, and vaccines that incorporate synthetic glycans can trigger stronger and more specific immune responses.

Glycomics is also essential for the development of biologics, a growing class of therapeutics that includes monoclonal antibodies, gene therapies, and cell-based treatments. Many biologics, such as therapeutic antibodies, rely on glycosylation for their stability, efficacy, and safety. Understanding and controlling glycosylation patterns during drug manufacturing is critical for ensuring that biologics function correctly and are safe for patients. Glycomics provides the tools needed to monitor and optimize glycosylation during production, helping pharmaceutical companies develop more effective and consistent biologic therapies.

In addition to therapeutics and diagnostics, glycomics is playing a pivotal role in advancing personalized medicine. Since glycan patterns can vary between individuals based on genetic and environmental factors, understanding these variations allows for the development of personalized treatments tailored to a patient’s specific glycan profile. This is particularly important in cancer, where tumors often exhibit unique glycosylation patterns that can be targeted with personalized therapies. As the field of glycomics continues to evolve, it will play an increasingly important role in shaping the future of precision medicine, enabling more effective treatments that are customized to individual patients’ molecular profiles.

What Factors Are Driving the Growth of the Glycomics/Glycobiology Market?

Several key factors are driving the rapid growth of the glycomics/glycobiology market, including the increasing demand for personalized medicine, advancements in drug development, the growing prevalence of complex diseases, and technological innovations in glycan analysis. First, the push toward personalized medicine is a major driver of the glycomics market. As healthcare shifts from a one-size-fits-all approach to more individualized treatments, glycomics offers the tools to identify unique glycan profiles that can be used to tailor therapies. This is particularly important in oncology, where cancer cells often exhibit specific glycan changes that can be targeted for more effective treatments. The ability to use glycan biomarkers for early disease detection and personalized treatment strategies is fueling the demand for glycomics technologies in research and clinical settings.

Second, advancements in drug development, particularly in the field of biologics and monoclonal antibodies, are contributing to the growth of the glycomics market. Many biologic drugs rely on glycosylation for their activity, stability, and safety, and controlling these glycan structures during drug production is essential for creating effective therapies. Pharmaceutical companies are increasingly investing in glycomics tools and technologies to optimize glycosylation in biologics, ensuring that these therapies meet the highest standards for efficacy and safety. This demand for precision in drug development is driving the adoption of glycomics in the pharmaceutical industry.

Third, the growing prevalence of complex diseases, such as cancer, autoimmune disorders, and neurodegenerative diseases, is increasing the need for advanced diagnostic and therapeutic solutions. Glycomics is uniquely positioned to address this need by offering insights into how changes in glycosylation contribute to disease progression. For example, glycan-based biomarkers are being developed for the early detection of cancers, while glycan-targeting therapies are being explored as novel treatments for autoimmune diseases and infectious diseases. As the global burden of these diseases continues to rise, the demand for glycomics-based solutions is expected to grow significantly.

Technological innovations in glycan analysis are also driving the expansion of the glycomics market. Advances in mass spectrometry, glycan arrays, and bioinformatics tools are enabling researchers to analyze glycans with greater speed, accuracy, and resolution. These technologies are making it easier for scientists to map the glycome, identify disease-specific glycan alterations, and develop new glycan-based therapies. The growing availability of high-throughput glycan analysis tools is accelerating research and expanding the commercial potential of glycomics in fields such as diagnostics, therapeutics, and vaccine development.

Additionally, increased funding for glycomics research and the establishment of specialized glycomics research centers are contributing to market growth. Governments, academic institutions, and private companies are investing heavily in glycomics research due to its potential to transform healthcare. Collaborative efforts between academia, industry, and healthcare providers are advancing the application of glycomics in clinical practice, further driving demand for glycomics tools and technologies.

In conclusion, the growth of the glycomics/glycobiology market is being driven by the increasing demand for personalized medicine, advancements in drug development, the growing prevalence of complex diseases, and technological innovations in glycan analysis. As glycomics continues to provide deeper insights into the role of glycans in health and disease, it will play a crucial role in shaping the future of diagnostics, therapeutics, and precision medicine across a wide range of medical and industrial applications.

Select Competitors (Total 152 Featured) -

  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Merck KgaA
  • New England Biolabs, Inc.
  • Prozyme, Inc.
  • Shimadzu Corporation
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Waters Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Glycomics / Glycobiology - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Interest in Glycomics for Understanding Disease Mechanisms Spurs Market Growth
    • Expansion of Glycobiology in Cancer and Immunology Research Drives Demand
    • Role of Glycomics in Developing Targeted Therapies and Personalized Medicine
    • Market Opportunities in Drug Discovery and Development Utilizing Glycomics
    • Role of Glycomics in Vaccine Development and Infectious Disease Research
    • Consumer Demand for Glycan-based Diagnostics and Biomarkers
    • Expansion of Glycomics in Neurological Research and Neurodegenerative Diseases
    • Role of Glycomics in Enhancing Stem Cell and Regenerative Medicine Research
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Glycomics / Glycobiology Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Glycomics / Glycobiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Glycomics / Glycobiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Enzymes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Drug Discovery & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • JAPAN
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • CHINA
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • EUROPE
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Glycomics / Glycobiology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Glycomics / Glycobiology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • FRANCE
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • GERMANY
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030

IV. COMPETITION